Remote Electrical Neuromodulation

Your Advantage in Migraine Control

Nerivio is an FDA-cleared, prescribed, Remote Electrical Neuromodulation (REN) wearable for the prevention and/or treatment of migraine in ages 8 and older. Safe, effective, and easy to use, Nerivio provides consistent migraine relief without systemic side effects that may disrupt your day.

No Drugs
No Needles
Non-Addictive
Non-Sedative
Non-Invasive
No Rebound
Headaches
No Systemic
Side Effects
Economically viable
Preventive &
Acute
FDA Cleared
Clinically
Proven
Safe
Effective
Discreet
Economically viable
From The Arm to The Brain

Harness the Power of Your Brain to Treat Migraine

Nerivio is the first-and-only Remote Electrical Neuromodulation (REN) wearable that harnesses the natural power of the brain to shut off migraine pain and symptoms without drugs or disruption. Using nerve stimulation initiated from the arm to the brain, Nerivio provides an innovative, non-invasive solution for migraine relief.

Complete Migraine Care

Support at Every Stage of Life

Nerivio provides effective relief for children (ages 8+), teens, and adults, offering migraine care tailored to every life stage.

Nerivio for

Adults

Migraine affects approximately 16% of the US
population [1] , and is the second leading cause of years lived with disability (YLDs). [2] With Nerivio, patients can effectively control their migraine and symptoms, without the common side effects of medications.

Nerivio for

Children (ages 8+)

Nerivio is the only prescribed preventive and dual treatment of migraine for children in this age group (8-11), and the first FDA-cleared, drug-free therapy for acute treatment of migraine in children.

Nerivio for

Teenagers

Adherence to pharmacological treatments is often low due to disruptive side effects. Nerivio seamlessly integrate into a teen's daily life—at home, school, or on the go—providing safe and effective treatment that is easy to follow.

Proven Migraine Relief

Based on Strong Scientific Evidence

Studies demonstrate that Nerivio provides safe and consistent migraine relief in the clinical and real-world setting. Data from our 22 peer reviewed publications include:

7 out of 10 patients
Achieved pain relief with Nerivio
(Hershey et al. 2020; Werner et al. 2024)
9 out of 10 patients
Demonstrated sustained pain relief and pain freedom at 24 hours
 (Hershey et al. 2020)
23% of patients
Achieved higher relief than with medication
 (Hershey et al. 2021)
After 2 months*
Reduction of 4 migraine days per month
(Tepper et al. 2023)
≥50% of patients
Experienced ≥50% reduction in moderate to severe headache days
(Tepper et al. 2023)
Favorable safety profile
No device-related adverse events reported in the clinical study
(Tepper et al. 2023)
2 out of 3 patients
Achieved pain relief with Nerivio
(Yarnitsky et al. 2019)
Over 1 out of 3 patients
Achieved pain freedom with Nerivio
(Yarnitsky et al. 2019)
8 out of 10 patients
Did not use prescription medications
(Aliai et al. 2022)